Tilorone

Tilorone (trade name Amixin IC) is the first recognized synthetic, small molecular weight compound that is an orally active interferon inducer. It is used as an antiviral drug.

History
Tilorone was developed in the 1970s by the RICHARDSON MERRELL INC (US Patent 3592819, Filed Dec. 30, 1968, Ser. No. 788,038) and resynthesized in the USSR in the Physico-Chemical Institute of the Academy of Sciences of UkrSSR by Ludmila A. Litvinova and coworkers ( 1975-1976). In the USSR it's antiviral and interferon inducing properties were investigated in the DI Ivanovski Institute of virology AMS (Moscow) by Felix I. Ershov and coworkers (1980 - 1986) resulted with 1st phase clinical trials in 1987-1988 (anti-HAV, Moscow), 2nd phase clinical trials in 1989-1991 (anti influenza), 3rd phase 1993 - 1995. In 1996 it was approved by Pharmacological committee of RF for the viral infections therapeutics and prophylaxis (flu, hepatitis A, B, herpes simplex). It has been widely used in Ukraine since March 2005. It is produced by InterChem, based in Odessa.

Pharmacology
Tilorone activates the production of interferon.

According to the results of clinical tests, conducted in Kiev, the efficacy of prophylactic action of tilorone was 93.7%.

Uses
Tilorone is used for different viral diseases: influenza, hepatitis, herpes, diarrhea and others. In addition, it is used in the treatment of multiple sclerosis, urinary tract infections and other viral and autoimmune diseases.